Tulasi Healthcare, a leading mental well-being platform based in Gurugram, has announced the launch of its latest Deep Transcranial Magnetic Stimulation (dTMS) therapy service. This innovative therapy aims to provide effective treatment for individuals facing treatment-resistant depression (TRD), helping them find renewed hope and relief from their symptoms.

Since its launch in July 2023, Tulasi Healthcare has successfully treated 4 patients with treatment-resistant depression. The emotional and mental-wellness platform aims to expand its reach and impact, with plans to treat 50 patients per month.

Each dTMS session lasts approximately 20 to 30 minutes, and the total number of sessions may vary depending on the prescribed treatment protocol, lasting up to 4-6 weeks or up to 12 weeks in some cases.

Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the US Food and Drug Administration (FDA), for the treatment of depression, specifically for individuals with TRD. Treatment-resistant depression is a form of depression that does not respond adequately to standard treatments, such as antidepressant medications and psychotherapy.

dTMS therapy works by delivering repetitive magnetic pulses to target specific brain regions, such as the left dorsolateral prefrontal cortex, inducing neuroplastic changes that enhance neural circuit connectivity and mood regulation. This advanced form of transcranial magnetic stimulation (TMS) has shown promising results in treating treatment-resistant obsessive-compulsive disorder (OCD) and depression.